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To assess the efficacy and safety of intravenous diltiazem, 
54 patients with inducible sustained supraventricular 
tachycardia received diltiazem, 0.25 mg/kg or 0.25 mg/kg, 
followed by 0.35 mg/kg body weight, or placebo in a 
double-blind, randomized study. Twenty patients had 
atrioventricular (AV) node reentrant tachycardia, whereas 
34 had orthodromic AV reciprocating tachycardia associ- 
ated with the Wolff-Parkinson-White syndrome. Supraven- 
tricular tachycardia was terminated in 24 (86%) of 28 
patients given intravenous diltiazem compared with 5 
(19%) of 26 given placebo (p = 0.0000014). Nineteen (95%) 
of 20 patients initially given placebo had termination of 
supraventricular tachycardia after receiving diltiazem. 
Overall, 43 (90%) of 48 patients receiving intravenous 
diltiazem had conversion of supraventricular tachycardia 
to sinus rhythm; the median time to tachycardia termina- 
tion was 2 min after initiation of a 2 min diltiazem infusion. 
Diltiazem is a calcium channel antagonist that has had 
extensive use as an antianginal agent (l-6). Electrophysio- 
logic studies have shown that it slows atrioventricular (AV) 
node conduction and prolongs AV node refractoriness (7,8), 
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All 20 patients (100%) with AV node reentrant tachy- 
cardia treated with diltiazem had conversion of tachycardia 
to sinus rhythm as did 26 (81%) of 30 patients with AV 
reciprocating tachycardia treated with diltiazem. Diltiazem 
prolonged refractoriness and slowed conduction of the AV 
node and thereby provided antiarrhythmic action to cause 
tachycardia termination. Diltiazem had no effect on the 
electrophysiologic properties of accessory AV connections. 
Adverse effects were seen in 3 (6%) of the 48 patients given 
diltiazem. 
For paroxysmal supraventricular tachycardia initiated 
in the electrophysiology laboratory, it is concluded that 
intravenous diltiazem is safe and very effective for acute 
tachycardia termination when the AV node is part of the 
reentrant circuit. 
(J Am Co11 Cardiol1989;13:53844) 
and additional studies have suggested that it is effective 
therapy for supraventricular tachyarrhythmias ($19). How- 
ever, there has been no placebo-controlled, randomized, 
double-blind study to test the efficacy of diltiazem for the 
acute treatment of reentrant supraventricular tachycardia. 
In this study, we used a double-blind, randomized, mul- 
ticenter protocol to test the efficacy of intravenous diltiazem 
hydrochloride against placebo for converting induced supra- 
ventricular tachycardia to sinus rhythm in the electrophysi- 
ology laboratory. 
Methods 
Study patients. Fifty-four patients with reproducibly in- 
duced, hemodynamically well tolerated supraventricular 
tachycardia lasting 15 min with a heart rate > 120 beats/min 
during electrophysiologic testing were enrolled in the study. 
There were 34 men and 20 women with a mean age of 41.3 
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years (range 17 to 79). Clinically, all patients had recurrent, 
symptomatic supraventricular tachycardia. Associated car- 
diac diagnoses included coronary artery disease in three, 
hypertension in six, valvular heart disease in two and 
cardiomyopathy in two patients. Patients with significant 
hepatic or renal disease were excluded. 
Electrophysiologic study. All patients gave informed con- 
sent before study participation. All cardiac medications were 
discontinued for ~5 half-lives before study. Patients were 
studied in the postabsorptive, lightly sedated state. With use 
of the conventional technique, a tripolar or quadripolar 
electrode catheter was introduced from the right femoral 
vein and advanced to the right atrium for the recording of 
His bundle electrograms (20). Another quadripolar electrode 
catheter was inserted into the left subclavian or right internal 
jugular vein and advanced into the coronary sinus for the 
recording of left atria1 electrograms. Two more quadripolar 
electrode catheters were introduced from the right femoral 
vein and advanced to the high right atrium and right ventricle 
for recording and pacing. An indwelling catheter was placed 
in the right femoral artery for blood pressure monitoring. 
Intracardiac electrograms were displayed simultaneously 
with electrocardiographic (ECG) leads on a multichannel 
oscilloscope and were recorded at paper speeds of 25 to 200 
mm/s. We used a programmed digital stimulator to deliver 
electric pulses of 2 ms duration at twice diastolic threshold. 
Programmed electrical stimulation consisting of atria1 and 
ventricular incremental pacing and extrastimulation was 
used to assess anterograde and retrograde AV conduction 
patterns, refractory periods and the ability to induce supra- 
ventricular tachycardia. 
Study design. After baseline electrophysiologic and he- 
modynamic variables were measured, supraventricular 
tachycardia was induced and observed for 2 15 min in each 
patient (Fig. IA). All patients were given a bolus injection of 
either diltiazem hydrochloride, 0.25 mg/kg body weight, or 
placebo (Dose A) according to a double-blind, randomized 
coding system. If the tachycardia converted to normal sinus 
rhythm within 15 min after the first injection (Drug Period I), 
the second injection was withheld. If the tachycardia did not 
- SVT 
Termlnatlon 
convert within 15 min of the first injection, a second bolus 
injection of either diltiazem hydrochloride, 0.35 mglkg, or 
placebo (Dose B) was given. If the conversion did not occur 
within 15 min after the second injection (Drug Period II), the 
tachycardia was terminated by programmed electrical stim- 
ulation. At the time of tachycardia termination or at the end 
of Drug Period II, electrophysiologic and hemodynamic 
measurements were repeated. 
If the tachycardia was not converted to sinus rhythm by 
the end of Drug Period II, the study drug was unblinded and 
those patients receiving placebo were entered into the open 
label phase of the study (Fig. 1B). In these patients, tachy- 
cardia was reinitiated and observed for 15 min, when diltia- 
zem hydrochloride, 0.25 mglkg, was administered. A 15 min 
observation period (Drug Period III) followed. If the tachy- 
cardia was not converted to sinus rhythm during Drug Period 
III, diltiazem hydrochloride, 0.35 mg/kg, was injected and a 
15 min observation period followed (Drug Period IV). If the 
tachycardia did not convert to sinus rhythm after Drug 
Period IV, it was terminated by programmed electrical 
stimulation, and final electrophysiologic and hemodynamic 
measurements were obtained. All infusions were given 
through an antecubital vein over a 2 min period. 
The diagnostic criteria for AV reciprocation with use of 
an accessory AV connection and AV node reentry were as 
previously described (21-24). We used the conventional 
definitions and measurements of AV conduction time and 
refractory periods (21-24) and defined a positive response to 
drug therapy as termination of supraventricular tachycardia 
within 15 min after completion of diltiazem or placebo 
infusion. 
Statistical analysis. The therapeutic responses to diltia- 
zem and placebo were compared with the use of Fisher’s 
exact test. Logistic regression was used to analyze drug 
interactions of supraventricular tachycardia subtypes. Blood 
pressure changes were analyzed by analysis of variance 
methods for repeated measures. All electrophysiologic var- 
iables were analyzed by one-way analysis of variance. Data 
are expressed as mean values f SEM. A p value <0.05 was 
considered statistically significant. 
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Table 1. Efficacy of Intravenous Diltiazem Versus Placebo for Table 2. Efficacy of Intravenous Diltiazem for Conversion of 
Conversion of Supraventricular Tachycardia to Sinus Rhythm in Supraventricular Tachycardia to Sinus Rhythm According to 
54 Patients Tachycardia Mechanism in 54 Patients 
Diltiazem Dose (m&g) 
Double blind 
Diltiazem Placebo 
0.25 
0.25 followed by 0.35 
Open label 
20 of 28 (71%)* 2 of 26 (%) 
24 of 28 (86%)* 5 of 26 (19%) 
0.25 17 of 20 (85%) - 
0.25 followed by 0.35 19 of 20 (95%) - 
*p < 0.001 versus placebo. 
Results 
Two electrophysiologic mechanisms for supraventricular 
tachycardia were seen in these 54 patients. Twenty patients 
had inducible AV node reentrant tachycardia of the usual 
slow-fast form (22,23). Thirty-four patients had inducible 
orthodromic AV reciprocating tachycardia with use of the 
AV node-His-Purkinje system for anterograde conduction 
and an accessory AV connection for retrograde conduction. 
Of these 34 patients, 19 had manifest and 15 had concealed 
Wolff-Parkinson-White syndrome. 
Diltiazem Dose (mg/kg) Diltiazem Placebo 
AV node reentrant 
tachycardia 
Double blind 
0.25 and 0.35 10 of 10 (loo%)* 2 of 10 (20%) 
Open label 
0.25 and 0.35 8of8(100%) - 
AV reciprocating 
tachycardia 
Double blind 
0.25 and 0.35 14 of 18 (78%) 3 of 16 (1%) 
Open label 
0.25 and 0.35 11 of 12 (92%) - 
*p = NS. AV reciprocating tachycardia response to double-blind diltia- 
zem, 0.25 and 0.35 mglkg. AV = atrioventricular; NS = not significant. 
to therapeutic response for diltiazem-treated patients was 2 
min after initiation of the 2 min drug infusion. 
Efficacy of intravenous diltiazem and placebo for conver- 
sion of supraventricular tachycardia to sinus rhythm (Table 
1). During Drug Period I, supraventricular tachycardia con- 
verted to sinus rhythm in 20 (71%) of 28 patients who 
received diltiazem, 0.25 mglkg, compared with 2 (9%) of 26 
who received placebo. This difference was statistically sig- 
nificant (p = O.OOOOO14). During Drug Period II, tachycardia 
converted to sinus rhythm in an additional 4 patients (24 
[86%] of 28) receiving diltiazem, 0.25 mg/kg or 0.25 mglkg 
followed by 0.35 mg/kg; tachycardia conversion also oc- 
curred in an additional 3 patients (5 [19%] of 26) receiving 
placebo (p = 0.0000014). 
Efficacy of intravenous diltiazem in AV node reentrant 
tachycardia and AV reciprocating tacbycardia (Table 2). 
Eighteen patients (100%) with AV node reentrant tachycar- 
dia treated with diltiazem had tachycardia conversion to 
sinus rhythm as did 25 (83%) of 30 patients with AV 
reciprocating tachycardia treated with diltiazem (p = NS). 
In the open label portion of the study, supraventricular 
tachycardia converted to sinus rhythm in 17 (85%) of 20 
patients during Drug Period III after diltiazem, 0.25 mg/kg. 
During Drug Period IV, after additional diltiazem, 0.35 mg/ 
kg, tachycardia conversion to sinus rhythm occurred in an 
additional two patients. Therefore, in 19 (95%) of 20 pa- 
tients, supraventricular tachycardia converted to sinus 
rhythm after diltiazem, 0.25 mg/kg or 0.25 mg/kg followed by 
0.35 mg/kg, during the open label portion of the study. One 
patient receiving placebo became hypotensive and did not 
enter the open label portion of the study. 
Significant electrophysiologic effects of intravenous diltia- 
zem during supraventricular tachycardia. Diltiazem, 0.25 
mg/kg, significantly increased the mean cycle length of 
supraventricular tachycardia (AV node reentrant tachycar- 
dia and AV reciprocating tachycardia) from 309 2 16 ms 
before to 337 ? 19 ms after drug administration; in patients 
given placebo the cycle length changed from 329 ? 9 ms 
before placebo to 309 rt 17 ms after placebo (p = 0.0001). In 
addition, the mean AH interval during supraventricular 
tachycardia increased from 152 + 33 ms before to 185 ? 33 
ms after diltiazem, 0.25 mgikg; in patients given placebo it 
changed from 166 + 13 ms before placebo to 164 t 63 ms 
after placebo (p = 0.0014). 
When the results from the blinded and open label portions 
of the study are combined, 43 (90%) of 48 patients who 
received diltiazem, 0.25 or 0.35 mg/kg, had conversion of 
supraventricular tachycardia to sinus rhythm. During Drug 
Periods I and II, the median time to therapeutic response 
after initiation of the 2 min drug infusion was 2.3 min for 
patients treated with diltiazem. For the combined double- 
blind and open label portions of the study, the median time 
Significant electrophysiologic effects of intravenous diltia- 
zem during programmed stimulation. After diltiazem, 0.25 
mg/kg, at a paced cycle length of 400 ms, the mean AV node 
effective refractory period and functional refractory period 
of patients with AV node reentrant tachycardia and AV 
reciprocating tachycardia increased from 246 ? 12 and 303 ? 
19 ms to 278 + 10 and 338 ? 12 ms, respectively. After 
placebo, at the same paced cycle length of 400 ms, the mean 
AV node effective refractory period and functional refrac- 
tory period of patients with AV node reentrant tachycardia 
and AV reciprocating tachycardia decreased from 234 t 9 
and 342 + 8 ms to 229 + 11 and 332 + 20 ms, respectively 
(p = 0.0019 and p = 0.005, respectively). After diltiazem, 
0.25 mg/kg, at a paced cycle length of 400 ms, the mean 
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anterograde effective refractory period of the accessory AV 
connection in patients with manifest Wolff-Parkinson-White 
syndrome changed from 281 + 18 to 273 +- 65 ms. In patients 
with manifest and concealed Wolff-Parkinson-White syn- 
drome, the mean retrograde effective refractory period of the 
accessory AV connection changed from 248 * 10 to 243 * 13 
ms after diltiazem, 0.25 m&g and at a paced cycle length of 
400 ms. After placebo, also at a paced cycle length of 400 ms, 
the mean anterograde refractory period of the accessory AV 
connection in patients with manifest Wolff-Parkinson-White 
syndrome changed from 30.5 ? 32 to 313 f 61 ms. (p = NS, 
compared with mean post-diltiazem anterograde effective 
refractory period values). In patients with manifest and 
concealed Wolff-Parkinson-White syndrome, the mean ret- 
rograde effective refractory period of the accessory AV 
connection changed from 255 it 12 to 251 of: 21 ms after 
placebo and at a paced cycle length of 400 ms (p = NS, 
compared with mean post-diltiazem retrograde effective 
refractory period values). 
Site of tachycardia termination. In patients with AV node 
reentrant tachycardia who had tachycardia conversion to 
sinus rhythm after intravenous diltiazem, the site of tachy- 
cardia interruption was always in the anterograde slow AV 
node pathway (Fig. 2). In those patients with AV recipro- 
cating tachycardia who demonstrated tachycardia conver- 
sion to sinus rhythm after diltiazem, the site of tachycardia 
interruption was exclusively in the AV node (Fig. 3). 
Hemodynamic effects of intravenous diltiazem. The mean 
percent change from baseline in systolic and diastolic blood 
pressures after infusion of diltiazem, 0.25 mg/kg, or placebo 
is displayed in Figure 4A and B, respectively. The mean 
percent systolic blood pressure change from baseline was 
+6.3 ? 2.9% after diltiazem compared with +2.2 2 2.2% 
after placebo (p = NS). The mean percent diastolic blood 
Figure 2. Termination of atrioventricular node reentrant tachycar- 
dia after intravenous diltiazem. A, In the control state, atrioventric- 
ular (AV) node reentrant tachycardia of the usual type is seen with 
anterograde conduction through the slow AV node pathway and 
retrograde conduction through the fast AV node pathway. The 
tachycardia cycle length is 400 ms and anterograde conduction time 
through the AV node (AH interval) is 360 ms. B, After intravenous 
diltiazem, 0.25 mglkg, anterograde conduction time through the AV 
node is lengthened to 390 to 470 ms, whereas retrograde conduction 
time through the fast pathway (HA interval) is unchanged compared 
with control. Tachycardia cycle length is prolonged, and tachycar- 
dia termination occurs by development of block in the anterograde 
slow AV node pathway (arrow). Surface electrocardiographic leads 
I, II and V, were recorded simultaneously with intracardiac high 
right atrium (HRA), His bundle (HBE) and distal coronary sinus 
(CS) electrograms. A = atria1 deflection; H = His bundle deflection. 
Numbers are in milliseconds. 
pressure change from baseline was t 1 +- 3% after diltiazem 
compared with 13 of: 2% after placebo (p = NS). 
Adverse effects. Three (6%) of the 48 patients who re- 
ceived intravenous diltiazem experienced adverse effects. 
One patient with manifest Wolff-Parkinson-White syndrome 
and orthodromic AV reciprocating tachycardia developed 
atria1 flutter with 1: 1 ventricular conduction over the acces- 
sory AV connection during Drug Period I. The cycle length 
during atria1 flutter was 210 ms and treatment with intrave- 
nous procainamide was required to control the ventricular 
response. This patient was the only patient among the 48 
patients given intravenous diltiazem to be removed from the 
study for an adverse effect. One patient with AV node 
reentrant tachycardia had an asymptomatic transient prolon- 
gation of the corrected sinus node recovery time from 220 to 
1,010 ms after intravenous diltiazem, 0.25 mg/kg. One pa- 
tient experienced transient generalized fatigue. 
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Figure 3. Termination of atrioventricular (AV) reciprocating tachy- 
cardia after intravenous diltiazem. A, In the control state, the AV 
node-His-Purkinje system is used for anterograde conduction and a 
left-sided lateral accessory connection for retrograde conduction. 
The tachycardia cycle length is 280 ms and the anterograde conduc- 
tion time through the AV node (AH interval) is 120 ms during 
tachycardia. B, After intravenous diltiazem, 0.25 mg/kg, antero- 
grade conduction time through the AV node is prolonged to 170 ms, 
whereas the retrograde conduction time through the accessory AV 
connection (ventriculoatrial conduction time) is unchanged com- 
pared with control. The tachycardia cycle length is prolonged to 330 
ms. Tachycardia termination occurs by development of block in the 
AV node (arrow). Trace layout and abbreviations are the same as for 
Figure 2. 
Discussion 
Our study shows that intravenous diltiazem is very effec- 
tive for the acute termination of reentrant supraventricular 
tachycardia involving the AV node as part of the reentrant 
circuit. Significant electrophysiologic effects of the drug 
were found to be limited to slowed conduction and pro- 
longed refractoriness in the AV node. These electrophysio- 
logic effects provide the basis for the antiarrhythmic action 
of intravenous diltiazem in the treatment of supraventricular 
tachycardia. 
Efficacy of intravenous diltiazem in supraventricular tachy- 
cardia termination. This study is the only large, placebo- 
controlled, randomized trial to demonstrate that intravenous 
diltiazem is highly efficacious for converting paroxysmal 
supraventricular tachycardia to sinus rhythm; the overall 
incidence of conversion was 90% in this study. These results 
confirm the efficacy results obtained in previous uncon- 
trolled, nonrandomized studies (lO,ll, 13,15-19) that re- 
ported conversion of paroxysmal supraventricular tachycar- 
dia to sinus rhythm in 60% to 100% of patients treated with 
intravenous diltiazem. In addition, we found no statistical 
difference in the efficacy of intravenous diltiazem for the 
conversion of AV node reentrant tachycardia or AV recip- 
rocating tachycardia to sinus rhythm. This finding extends 
the results of other reports (8,10,13,14,17,19) that were 
limited by small patient populations but also suggested that 
SBP PERCENT CHANGE MEANS AND STANDARD ERRORS 
DURING PERIOD 1 
-L 
I I I I 
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TIME (MINUTES FROM STARTOF INFUSION) 
B DBP PERCENT CHANGE MEANS AND STANDARD ERRORS 
DURING PERIOD 1 
0 2 7 12 17 
TIME (MINUTES FROM START OF INFUSION) 
Figure 4. Percent change in mean blood pressure after intravenous 
diltiazem (D), 0.25 mg/kg, and placebo (P). A, Mean change in 
systolic blood pressure @BP) plotted against time after onset of 
infusion. B, Mean change in diastolic blood pressure (DBP) plotted 
against time after onset of infusion. Vertical bars indicate SEM. 
Solid line indicates diltiazem-treated group and broken line indicates 
placebo-treated group. 
intravenous diltiazem has a comparable efficacy when used 
for either AV node reentrant tachycardia or AV reciprocat- 
ing tachycardia. 
Electrophysiologic effects and antiarrhythmic action of 
intravenous diltiazem. This study shows that the significant 
electrophysiologic effects of intravenous diltiazem were the 
prolongation of AV node effective and functional refractory 
periods and the prolongation of AV node conduction (AH 
interval) during supraventricular tachycardia. After diltia- 
zem infusion, no change was seen in the electrophysiologic 
properties of the accessory AV connection in patients with 
the Wolff-Parkinson-White syndrome. These findings are 
similar to previously reported electrophysiologic effects of 
intravenous diltiazem (8,10,13,14,17,19,25). 
In this study, the slow AV node pathway was the site of 
diltiazem-mediated tachycardia termination in all patients 
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with AV node reentrant tachycardia. This finding agrees 
with previous reports (10,13) that AV node reentrant tachy- 
cardia termination is due to a diltiazem-mediated anti- 
arrhythmic effect on the slow AV node pathway. However, 
other reports (14,17,19) have suggested that the antiarrhyth- 
mic action of intravenous diltiazem in AV node reentrant 
tachycardia can affect both slow and fast AV node path- 
ways. All patients with orthodromic AV reciprocating tachy- 
cardia who had diltiazem-mediated tachycardia termination 
showed the antiarrhythmic effect of diltiazem to occur 
exclusively in the AV node. These results are in agreement 
with other studies (10,13,14,17,19,25). 
This study, therefore, shows that the antiarrhythmic 
action of intravenous diltiazem in reentrant supraventricular 
tachycardia involving the AV node as part of the reentrant 
circuit is due to diltiazem-mediated depression of conduction 
and prolongation of refractoriness in the AV node. 
Hemodynamic effects of intravenous diltiazem. In this 
study, an insignificant increase in the mean percent change 
in systolic blood pressure and no significant alteration in the 
mean percent change in diastolic blood pressure were noted 
after intravenous diltiazem compared with findings after 
placebo. Mild systolic and diastolic hypotension have been 
observed in some patients after treatment with intravenous 
diltiazem for supraventricular tachycardia (11,14,15). How- 
ever, one other report (13) did not observe hypotension after 
intravenous diltiazem for supraventricular tachycardia. We 
speculate that the insignificant increase in mean percent 
change in systolic blood pressure seen after intravenous 
diltiazem compared with after placebo in this study may 
reflect a persistent, relative hypotension in the placebo- 
treated group due to continued supraventricular tachycardia. 
Adverse effects after intravenous diltiazem. Our study 
documents a low overall incidence of adverse events after 
infusion of intravenous diltiazem for electrically induced 
supraventricular tachycardia. Two of the three patients who 
developed adverse effects after intravenous diltiazem had 
mild side effects and did not require therapy. However, our 
experience with one patient with the Wolff-Parkinson-White 
syndrome, who developed atria1 flutter with I : 1 ventricular 
conduction after intravenous diltiazem, was similar to that 
reported by others (19,25) and supports the view that intra- 
venous diltiazem should not be used for the treatment or 
prevention of atria1 fibrillation-flutter in patients with ven- 
tricular pre-excitation (Wolff-Parkinson-White syndrome). 
The low incidence of adverse effects observed in our study 
has been reported by others (11,13-15,17,18,25). 
Comparison with verapamil. Intravenous diltiazem ap- 
pears to have electrophysiologic properties similar to those 
of verapamil (8) and shows comparable efficacy in convert- 
ing supraventricular tachycardia to sinus rhythm (26-3 I). 
Although the side effect profile of intravenous diltiazem 
appears favorable, further study is necessary before it can be 
concluded that intravenous diltiazem has significantly fewer 
side effects than does intravenous verapamil (32-34). 
Clinical implications. Intravenous diltiazem in the dosage 
of 0.25 and 0.35 mg/kg is safe and effective in the conversion 
of induced reentrant paroxysmal supraventricular tachycar- 
dia to sinus rhythm. Diltiazem interrupts AV node reentrant 
tachycardia and AV reciprocating tachycardia by prolonging 
conduction and lengthening refractoriness in the AV node. It 
exerts no significant effects on accessory AV pathway con- 
duction or refractoriness. Diltiazem should be avoided in 
patients with manifest Wolff-Parkinson-White syndrome 
with a tendency for the development of atria1 fibrillation- 
flutter. 
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